Revising the model for vaccine development: a step towards tuberculosis immunity
Article Sidebar
Published:
Aug 26, 2021
Keywords:
Tuberculosis, COVID-19, vaccines
Main Article Content
Article Details
Section
Commentary
- Authors publishing in the UOJM retain copyright of their articles, including all the drafts and the final published version in the journal.
- While UOJM does not retain any rights to the articles submitted, by agreeing to publish in UOJM, authors are granting the journal right of first publication and distribution rights of their articles.
- Authors are free to submit their works to other publications, including journals, institutional repositories or books, with an acknowledgment of its initial publication in UOJM.
- Copies of UOJM are distributed both in print and online, and all materials will be publicly available online. The journal holds no legal responsibility as to how these materials will be used by the public.
- Please ensure that all authors, co-authors and investigators have read and agree to these terms.
- Works are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
1. Government of Canada. Pfizer-BioNTech COVID-19 Vaccine (tozinameran) [Internet]. Government of Canada; [updated 2021 Mar 26; cited 2021 Mar 26]. Available from: https://covid-vaccine.canada.ca/pfizer-biontech-covid-19-vaccine/product-details
2. World Health Organization. Global tuberculosis report 2020. Geneva (CH): WHO Press; 2020. 232 p. Licence: CC BY-NC-SA 3.0 IGO.
3. Vachon J, Gallant V, Siu W. Tuberculosis in Canada, 2016. CCDR. 2018 Mar 1;44(3/4):75–81.
4. World Health Organization. Global tuberculosis control 2009: epidemiology, strategy, financing. WHO Press; 2009. 314 p. ISBN 978 92 4 156380 2
5. Young C, Walzl G, Du Plessis N. Therapeutic host-directed strategies to improve outcome in tuberculosis. Mucosal Immunol. 2020 Mar;13(2):190–204.
6. World Health Organization. Lack of new antibiotics threatens global efforts to contain drug-resistant infections [Internet]. World Health Organization; 2020 Jan 17 [cited 2021 Mar 26]. Available from: https://www.who.int/news/item/17-01-2020-lack-of-new-antibiotics-threatens-global-efforts-to-contain-drug-resistant-infections#:~:text=Declining%20private%20investment%20and%20lack,weak%20pipeline%20for%20antibiotic%20agents
7. Public Health Agency of Canada. Canadian Tuberculosis Standards 7th Edition. Ontario (CA): Government of Canada; 2014. Chapter 16: Bacille Calmette-Guérin (BCG) vaccination in Canada; p. 405.
8. Martin C, Aguilo N, Marinova D, Gonzalo-Asensio J. Update on TB Vaccine Pipeline. Applied Sciences. 2020 Apr 10;10(7):2632.
9. Kovesi T. Respiratory disease in Canadian First Nations and Inuit children. Paediatr Child Health. 2012 Aug 1;17(7):376-380.
10. Patterson M, Flinn S, Barker K. Addressing tuberculosis among Inuit in Canada. CCDR. 2018 Mar 1;44(3/4):82–5.
11. World Health Organization. Coronavirus update 45: Update on COVID-19 vaccine development [Internet]. World Health Organization; [updated 2020 Dec 21; cited 2021 Mar 26]. Available from: https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update45-vaccines-developement.pdf?sfvrsn=13098bfc_5
12. Government of Canada. Backgrounder – Government of Canada investments in COVID-19 vaccines, therapeutics and biomanufacturing capacity [Internet]. Government of Canada; 2021 Feb 2 [cited 2021 Mar 26]. Available from: https://www.canada.ca/en/innovation-science-economic-development/news/2021/02/backgrounder--government-of-canada-investments-in-covid-19-vaccines-and-biomanufacturing-capacity.html
13. Treatment Action Group. Tuberculosis research funding trends 2005-2019. New York (US); 2020. 62 p.
14. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018 Apr;17(4):261–79.
15. Li H, Liu L, Zhang W, Zhang X, Zheng J, Li L, et al. Analysis of the antigenic properties of membrane proteins of Mycobacterium tuberculosis. Sci Rep. 2019 Dec;9(1):3042.
2. World Health Organization. Global tuberculosis report 2020. Geneva (CH): WHO Press; 2020. 232 p. Licence: CC BY-NC-SA 3.0 IGO.
3. Vachon J, Gallant V, Siu W. Tuberculosis in Canada, 2016. CCDR. 2018 Mar 1;44(3/4):75–81.
4. World Health Organization. Global tuberculosis control 2009: epidemiology, strategy, financing. WHO Press; 2009. 314 p. ISBN 978 92 4 156380 2
5. Young C, Walzl G, Du Plessis N. Therapeutic host-directed strategies to improve outcome in tuberculosis. Mucosal Immunol. 2020 Mar;13(2):190–204.
6. World Health Organization. Lack of new antibiotics threatens global efforts to contain drug-resistant infections [Internet]. World Health Organization; 2020 Jan 17 [cited 2021 Mar 26]. Available from: https://www.who.int/news/item/17-01-2020-lack-of-new-antibiotics-threatens-global-efforts-to-contain-drug-resistant-infections#:~:text=Declining%20private%20investment%20and%20lack,weak%20pipeline%20for%20antibiotic%20agents
7. Public Health Agency of Canada. Canadian Tuberculosis Standards 7th Edition. Ontario (CA): Government of Canada; 2014. Chapter 16: Bacille Calmette-Guérin (BCG) vaccination in Canada; p. 405.
8. Martin C, Aguilo N, Marinova D, Gonzalo-Asensio J. Update on TB Vaccine Pipeline. Applied Sciences. 2020 Apr 10;10(7):2632.
9. Kovesi T. Respiratory disease in Canadian First Nations and Inuit children. Paediatr Child Health. 2012 Aug 1;17(7):376-380.
10. Patterson M, Flinn S, Barker K. Addressing tuberculosis among Inuit in Canada. CCDR. 2018 Mar 1;44(3/4):82–5.
11. World Health Organization. Coronavirus update 45: Update on COVID-19 vaccine development [Internet]. World Health Organization; [updated 2020 Dec 21; cited 2021 Mar 26]. Available from: https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update45-vaccines-developement.pdf?sfvrsn=13098bfc_5
12. Government of Canada. Backgrounder – Government of Canada investments in COVID-19 vaccines, therapeutics and biomanufacturing capacity [Internet]. Government of Canada; 2021 Feb 2 [cited 2021 Mar 26]. Available from: https://www.canada.ca/en/innovation-science-economic-development/news/2021/02/backgrounder--government-of-canada-investments-in-covid-19-vaccines-and-biomanufacturing-capacity.html
13. Treatment Action Group. Tuberculosis research funding trends 2005-2019. New York (US); 2020. 62 p.
14. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018 Apr;17(4):261–79.
15. Li H, Liu L, Zhang W, Zhang X, Zheng J, Li L, et al. Analysis of the antigenic properties of membrane proteins of Mycobacterium tuberculosis. Sci Rep. 2019 Dec;9(1):3042.